GENB

Generate Biomedicines

• Reuters·2d ago

  Generate Biomedicines publishes corporate presentation on programmable biology drug design platform

• Seeking Alpha·3d ago

  Largest IPOs of the last 90 days register mixed debut

• Reuters·03/27 20:14

  UPDATE 2-Kailera Therapeutics files for US IPO

• NASDAQ·03/27 18:18

  Friday's ETF Movers: SLVR, ARKG

• Reuters·03/25 17:52

  BUZZ-Morgan Stanley bullish on Generate Biomedicines, cites strength of lead asthma drug

• TipRanks·03/25 14:45

  Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating

• Reuters·03/25 11:01

  GENERATE BIOMEDICINES INC <GENB.O>: MORGAN STANLEY INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $20

• Reuters·03/25 08:01

  U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources

• Seeking Alpha·03/24 19:15

  Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler

• Dow Jones·03/24 17:34

  Generate Biomedicines Price Target Announced at $26.00/Share by Goldman Sachs

• Benzinga·03/24 17:23

  Goldman Sachs Initiates Coverage On Generate Biomedicines with Buy Rating, Announces Price Target of $26

• Dow Jones·03/24 13:48

  Generate Biomedicines Price Target Announced at $20.00/Share by Morgan Stanley

• Dow Jones·03/24 13:48

  Generate Biomedicines Initiated at Overweight by Morgan Stanley

• Dow Jones·03/24 13:02

  Generate Biomedicines Price Target Announced at $24.00/Share by Piper Sandler

• Reuters·03/24 12:44

  GENERATE BIOMEDICINES INC <GENB.O>: MORGAN STANLEY INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET $20